Clinical Efficacy and Mechanism Exploration of MR-61 in Delaying the Progression of Myopia
Clinical Efficacy and Mechanism Exploration of MR-61 in Delaying the Progression of Myopia: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial
Second Affiliated Hospital of Nanchang University
164 participants
Oct 1, 2025
INTERVENTIONAL
Conditions
Summary
To investigate whether probiotic MR-61 can assist in slowing down the progression rate of myopia (a prospective randomized controlled study).
Eligibility
Inclusion Criteria4
- Myopia is defined as spherical equivalent (SE) ≤ -0.5D.
- Aged between 3 and 18 years, with no restriction on gender.
- Cylinder power ≤ 1.50D; anisometropia of SE between both eyes ≤ 1.50D.
- The subject has sufficient compliance with the study follow-up; the subject or their guardian has the intention to receive treatment and has signed the informed consent form.
Exclusion Criteria6
- Presence of other concomitant ocular diseases;
- Abnormal findings on clinical slit-lamp examination;
- Existence of amblyopia, manifest strabismus, esotropia, or other congenital ocular diseases;
- Individuals with abnormal intraocular pressure or abnormal axial length of the eye;
- Either or both parents having a spherical equivalent (SE) ≤ -6.00D;
- Other conditions inconsistent with this study.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Oral administration of the investigational probiotic powder MR-61. The primary component is Bifidobacterium. Dosage: one sachet, 2-3 times daily, for 3 months.
Oral administration of a matched placebo powder. Dosage: one sachet, 2-3 times daily, for 3 months.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07298824